These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31254273)

  • 1. Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007).
    Kuti JL; Kim A; Cloutier DJ; Nicolau DP
    Infect Dis Ther; 2019 Sep; 8(3):383-396. PubMed ID: 31254273
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Abdelraouf K; Kim A; Krause KM; Nicolau DP
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Activities of Novel Therapeutic Agents against Molecularly Characterized Clinical Carbapenem-Resistant
    Teo JQ; Chang HY; Tan SH; Tang CY; Ong RT; Ko KKK; Chung SJ; Tan TT; Kwa AL
    Microbiol Spectr; 2023 Jun; 11(3):e0100223. PubMed ID: 37184408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Clin Ther; 2019 Aug; 41(8):1453-1462. PubMed ID: 31248681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Safety of Meropenem-Colistin versus Meropenem-Tigecycline in Patients with Carbapenem-Resistant
    Park JM; Yang KS; Chung YS; Lee KB; Kim JY; Kim SB; Sohn JW; Yoon YK
    Antibiotics (Basel); 2021 Jul; 10(8):. PubMed ID: 34438953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections.
    Ruiz J; Ramirez P; Villarreal E; Gordon M; Sánchez MÁ; Martín M; Castellanos-Ortega Á
    SAGE Open Med; 2020; 8():2050312120958897. PubMed ID: 32999720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.
    Cies JJ; Moore WS; Enache A; Chopra A
    J Pediatr Pharmacol Ther; 2017; 22(4):276-285. PubMed ID: 28943823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.
    Bhavnani SM; Rubino CM; Hammel JP; Forrest A; Dartois N; Cooper CA; Korth-Bradley J; Ambrose PG
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1065-72. PubMed ID: 22143524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates.
    Nicasio AM; Crandon JL; Nicolau DP
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2756-61. PubMed ID: 19364850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
    Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
    J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of tigecycline alone or in combination for experimental infections by KPC carbapenemase-producing Klebsiella pneumoniae.
    Fergadaki S; Renieris G; Machairas N; Sabracos L; Droggiti DI; Misiakos E; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2021 Sep; 58(3):106384. PubMed ID: 34161789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
    Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
    Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India.
    Khare V; Gupta P; Haider F; Begum R
    J Clin Diagn Res; 2017 Mar; 11(3):DC18-DC21. PubMed ID: 28511383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically Ill Patients.
    Zhao YC; Zou Y; Xiao YW; Wang F; Zhang BK; Xiang DX; Yu F; Luo H; Sandaradura I; Yan M
    Infect Dis Ther; 2022 Feb; 11(1):201-216. PubMed ID: 34748194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.